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ABSTRACT
Shigellosis is a major cause of diarrhoea-related morbidity and mortality, especially in developing
countries. Effective antibiotic treatment reduces the average duration of illness by reducing faecal
excretion of the bacterium and preventing further transmission and potentially lethal complications.
Treatment of shigellosis is currently limited by the high prevalence of multidrug-resistant strains of
Shigella. Although ﬂuoroquinolones are currently effective in treating adults, resistance to ﬂuoro-
quinolones among Shigella spp. is emerging, and their use in children is subject to limitations.
Azithromycin and third-generation cephalosporins are also effective in the treatment of shigellosis, but
monitoring of Shigella isolates to detect the emergence of resistance is essential.
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Shigellosis is a major cause of diarrhoea-related
morbidity and mortality, especially in developing
countries. Recently, it was estimated that 91
million individuals worldwide contract shigello-
sis each year; in Asia, 410 000 children, mostly
malnourished, die [1]. Treatment of shigellosis
includes both rehydration and antimicrobial ther-
apy. Dysentery caused by Shigella is not usually
associated with marked loss of ﬂuid and electro-
lytes. However, if dehydration is detected, it can
usually be managed with oral rehydration ther-
apy. Appropriate antibiotic therapy alleviates the
dysenteric syndromes, fever and abdominal
cramps, reduces the average duration of pathogen
excretion, interrupts further transmission of dis-
ease, and reduces the risk of potentially lethal
complications [2].
Diarrhoea caused by Shigella can usually be
treated effectively by a 5-day course of anti-
microbial agents, as advocated by the WHO [3].
However, antimicrobial resistance has compli-
cated the treatment of shigellosis since the 1940s,
when sulphonamide resistance among Shigella
isolates was ﬁrst recognised in Japan. Subse-
quently, Shigella acquired resistance to tetra-
cycline and chloramphenicol during the 1950s.
When Shigella developed resistance to tetra-
cyclines, ampicillin became the drug of choice;
however, ampicillin-resistant strains appeared
in the early 1980s and became widespread in
Asia and Africa. Co-trimoxazole then became
the preferred drug, and remained effective until
the middle of the 1980s, when resistance to this
antibiotic was observed; thus, in the early 1980s,
100% of Shigella strains isolated in Dhaka, Ban-
gladesh, were susceptible to co-trimoxazole,
whereas only 45% were susceptible 4 years later.
The emergence and dissemination of multi-
drug-resistant strains of Shigella is now an
increasing global health problem that is compli-
cating the therapeutic management of cases of
shigellosis [4]. As an example, >60% of Shigella
dysenteriae type 1 isolates were resistant to
co-trimoxazole and ampicillin during an exten-
sive epidemic in eastern India in 1984 [5]. This
emerging problem led to a quest for alternative
effective oral antibiotics. Despite the failure of
nalidixic acid to rapidly terminate faecal excretion
of Shigella, highly encouraging results were
obtained at this time with this relatively inexpen-
sive and effective drug for the treatment of
multiresistant S. dysenteriae type 1 infection [6].
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However, within a short period, widespread use
of nalidixic acid resulted in the emergence of
nalidixic acid-resistant S. dysenteriae type 1 strains
in several parts of the world, including India [7].
Fluoroquinolones are related in structure to
nalidixic acid and are highly effective in vitro
against Shigella; they have therefore become the
preferred agents for the treatment of shigellosis
[8]. Moreover, several studies have shown that
these agents reach high concentrations in serum
and faeces [9], thereby offering signiﬁcant advan-
tages in the treatment of shigellosis. Also, simpli-
ﬁed treatment regimens (two doses per day for
3 days) have been shown to be very effective
against all species of Shigella. Multiple trials have
supported the clinical efﬁcacy of norﬂoxacin and
ciproﬂoxacin in the treatment of shigellosis in
adults [10,11]. However, the use of these agents to
treat children has been limited by the possibility
of ﬂuoroquinolone-induced joint ⁄ cartilage toxic-
ity, observed mainly in juvenile animal studies
[12]. It has been suggested that the use of
ﬂuoroquinolones in the paediatric setting should
be limited to multidrug-resistant enteric infec-
tions [13], and several reports have now docu-
mented that short-term treatment of children with
ﬂuoroquinolones has no adverse effects [14–16].
On the basis of its efﬁcacy, safety and relatively
low cost, ciproﬂoxacin has been recommended by
the WHO as the ﬁrst-line antibiotic for treatment
of shigellosis, and use of nalidixic acid is not
encouraged, even in areas where it is still effective
against Shigella [17]. However, the emergence of
ﬂuoroquinolone resistance among Shigella spp. has
now been documented in many countries [18–21].
At present, ﬂuoroquinolone-resistant Shigella
strains remain susceptible to some other antimi-
crobial agents, e.g., the macrolides (azithromycin)
or third-generation cephalosporins (ceﬁxime ⁄
ceftriaxone). These agents have been reported to
be effective for the treatment ofmoderate-to-severe
shigellosis caused by multidrug-resistant Shigella
strains [22,23], but cephalosporin resistance has
also been reported [24,25].
Because of concerns about increasing resistance
and side-effects, great expectations have been
raised for the use of antimicrobial agents that are
not absorbed from the gastrointestinal tract, and
which therefore tend to be associated with fairly
low resistance rates and few adverse effects. One
such agent, rifaximin, a non-absorbed rifamycin
derivative, has been shown to be effective against
enteric pathogens [26,27]. Nevertheless, more
data are required to properly evaluate its efﬁcacy
for the treatment of invasive diarrhoea. In addi-
tion, use of a supplemented protein-rich diet
during convalescence signiﬁcantly enhances
catch-up growth, while prolonged use of zinc
supplements has both therapeutic and preventive
impacts on diarrhoeal illness.
After considering all the pros and cons of
different antimicrobial agents for the treatment of
shigellosis, ﬂuoroquinolones currently remain the
drug of choice for treating shigellosis in adults. In
children, azithromycin, or a short course of a
quinolone (for severe disease), might be consid-
ered. However, for areas in which shigellosis is
endemic, recommendations on antibiotic selection
must be periodically updated according to the
local antimicrobial resistance patterns of Shigella
isolates. Shifts in the prevalence of serogroups
and changing patterns of antimicrobial suscepti-
bilities among Shigella isolates pose major difﬁ-
culties in selecting an appropriate drug for the
treatment of shigellosis [28]. There is an urgent
need for updating the guidelines for the treatment
of shigellosis in developing countries. Newer
derivatives of several antimicrobial agents are
currently being developed and marketed. How-
ever, following their indiscriminate use, resis-
tance to these newly introduced agents is already
being reported.
In conclusion, rationalised use of antimicrobial
agents is essential for the future control of
antimicrobial resistance, but will be very difﬁcult
to achieve. While antimicrobial agents undoubt-
edly play a major role in reducing mortality
among patients suffering from shigellosis, the
most effective approach against shigellosis in
developing countries rests on the need to improve
environmental sanitation and personal hygiene,
to maintain breast-feeding of infants until the age
of 6 months, to improve nutrition (which is a risk-
factor for children), and to develop safe and
effective vaccines.
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